레바미피드의 제조방법
    61.
    发明授权
    레바미피드의 제조방법 失效
    制备瑞巴派特的方法

    公开(公告)号:KR100766578B1

    公开(公告)日:2007-10-11

    申请号:KR1020010080842

    申请日:2001-12-18

    Abstract: 본 발명은 레바미피드의 제조방법에 관한 것으로서, 4-(브로모메틸)-1,2-디히드로-2-퀴놀리논과 디에틸 2-[(4-클로로벤조일)아미노]말로네이트를 반응시켜 생성된 반응중간체를 염기성 화합물로 처리하여 다음 화학식 1로 표시되는 레바미피드를 합성하는 방법으로서, 종래 방법이 수행하는 아미노기 보호반응 및 탈보호반응을 생략할 수 있고, 또한 반응중간체를 염기성 화합물로 처리하여 가수분해 반응과 탈탄산반응을 한 번의 공정으로 수행하는 등 전체적인 반응공정이 단순화되면서도 제조수율도 크게 향상된 효과를 가지는 레바미피드의 개선된 제조방법에 관한 것이다.
    [화학식 1]

    레바미피드

    퀴놀론카르복실산 유도체
    62.
    发明授权

    公开(公告)号:KR100566346B1

    公开(公告)日:2006-11-10

    申请号:KR1019980024391

    申请日:1998-06-26

    Abstract: 본 발명은 기존의 퀴놀론계 항생제에 비해 우수하고도 광범위한 항균활성을 갖는 퀴놀론카르복실산 유도체에 관한 것으로서, 더욱 상세하게는 7-[8-(알콕시이미노)-2,6-디아자스피로[3.4]옥트-6-일]의 유도체를 치환체로 갖는 다음 화학식 1로 표시되는 신규한 퀴놀론카르복실산 유도체, 이의 약제학적으로 허용가능한 염, 이의 이성질체 및 이의 제조방법에 관한 것이다.
    [화학식 1]

    상기 화학식에서, A는 CH, CF, C-Cl, CO-CH
    3, 또는
    N이고, Y는 수소 또는 아미노이고, R
    1 은 사이클로프로필 또는 2,4-디플루오로페닐이고, R
    2 는
    C
    1-4 의 저급알킬이고, R
    3 은 수소 또는 C
    1-4 의 저급알킬이다.

    4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
    64.
    发明授权
    4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도 有权
    4 - [(4-티아졸릴)페녹시]알콕시 - 벤즈아미딘유도체의골다공증치치제제로서의용도

    公开(公告)号:KR100454767B1

    公开(公告)日:2004-11-03

    申请号:KR1020010043490

    申请日:2001-07-19

    CPC classification number: A61K31/426 Y10S514/878

    Abstract: 본 발명은 류코트리엔-B
    4 (Leukotriene-B
    4 ; 이하 "LTB-4"로 약칭한다)의 수용체 길항작용을 갖는 것으로 알려진 하기 화학식 1로 표시되는 4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}-벤즈아미딘 또는 N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}-벤즈아미딘의 골다공증의 예방 및 치료제로서의 용도에 관한 것이다.
    [화학식 1]

    상기 식에서 R은 H 또는 OH이다.

    Abstract translation: 本发明涉及含有下式1表示的4 - [(4-噻唑基)苯氧基]烷氧基 - 苄脒衍生物用于预防和治疗骨质疏松症的药物组合物,更具体地涉及4- {5- [4 - (5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基} - 苄脒或N-羟基-4- {5- [4-(5-异丙基-2-甲基 - 噻唑-4-基)苯氧基]戊氧基} - 苄脒作为用于预防和治疗骨质疏松症的药物组合物,其已知为白三烯-B4受体的拮抗剂。 [通式1]其中,R是氢原子或羟基。

    신규설포닐이미다졸론유도체
    65.
    发明授权
    신규설포닐이미다졸론유도체 失效
    新型磺酰基咪唑啉酮衍生物

    公开(公告)号:KR100435085B1

    公开(公告)日:2004-08-18

    申请号:KR1019960053450

    申请日:1996-11-12

    Abstract: PURPOSE: Provided are a novel sulfonyl-imidazolone derivative of the formula(1) and its pharmaceutically acceptable salt, a manufacturing method thereof and an anti-tumor composition containing the same as an active ingredient. CONSTITUTION: The 4-phenyl-1-(indolin-5-sulfonyl)-2-imidazolone derivative is represented by the formula(1), wherein R is chloroacetyl, C1-C5 alkylamino acetyl, C1-C4 alkoxy carbonyl. benzoyl, nitrobenzoyl, aminobenzoyl, ethoxybenzoyl, chlorobenzoyl, chloroacetyl aminobenzoyl, furanoyl, thiophenoyl and C1-C6 alkylcarbamoyl; and R1 is hydrogen or C1-C4 lower alcohol. The compound of the formula(1) is manufactured by reacting a compound of the formula(A) and a compound of the formula(B).

    (S)-이성체형태의인돌린설포닐우레아유도체
    66.
    发明授权
    (S)-이성체형태의인돌린설포닐우레아유도체 失效
    (S) - 吲哚基磺酰脲衍生物的异构形式

    公开(公告)号:KR100437670B1

    公开(公告)日:2004-08-16

    申请号:KR1019970019365

    申请日:1997-05-19

    Abstract: PURPOSE: (S)-Isomer type indoline sulfonyl urea derivatives, a preparation method thereof and a pharmaceutical composition comprising the same are provided. The derivatives have improved anticancer activity and improved hydrophobic properties so as to be easily absorbed into the human body. CONSTITUTION: The (S)-4-phenyl-1-(N-(4-amino-benzoyl)-indoline-5-sulfonyl)- 4,5-dihydro-2-imidazolone derivatives are represented by the formula (1), wherein R is hydrogen, or an amino acid residue which is linked through an amide bond, and selected from glycine, alanine, valine, leucine, methionine, proline and phenylalanine. The method for preparing a compound of the formula (1a) comprises the steps of: combining a compound of the formula (7) with a compound of the formula (8) to prepare (S)-4-phenyl-1-(indoline-5-sulfonyl)-4,5-dihydro-2-imidazolone of the formula (3); reacting the compound of the formula (3) with 4-nitrobenzoylchloride of the formula (4); and reducing a nitro group of the resulting product. The method for preparing a compound of the formula (1b) comprises the steps of: condensing the compound of the formula (1a) with am amino acid of which amino group is protected with t-butoxycarbonyl; and deprotecting the amino group, wherein R' is an amino acid residue which is linked through an amide bond, and selected from glycine, alanine, valine, leucine, methionine, proline and phenylalanine.

    구강점막 부착형 필름제제
    67.
    发明公开
    구강점막 부착형 필름제제 有权
    口腔胶囊

    公开(公告)号:KR1020030062139A

    公开(公告)日:2003-07-23

    申请号:KR1020020002577

    申请日:2002-01-16

    CPC classification number: A61K9/006 A61K47/10 A61K47/32 A61K47/38

    Abstract: PURPOSE: A film applicable to the oral mucosa comprising two layers such as a protective layer and an adhesive layer which contain a drug is provided to effectively delivery the drug without changing the formulation. The film causes no foreign body sensation when applied to oral mucosa and has excellent convenience and efficiency in the preparation process. CONSTITUTION: An oral mucoadhesive film comprises: an adhesion layer containing 5 to 80% by weight of each of a polyacrylic acid-based polymer and a cellulose-based polymer, 5 to 70% by weight of poloxamer, 0.05 to 20% by weight of a drug absorbable through the oral mucosa and 0.1 to 10% by weight of a plasticizer; and a protective layer containing 5 to 50% by weight of a water-insoluble, water-impermeable polymer and 0.1 to 10% by weight of a plasticizer. The film has a thickness of 50 to 300 microns.

    Abstract translation: 目的:提供适用于包含两层如口服粘膜的保护层和含有药物的粘合剂层的膜,以有效地输送药物而不改变制剂。 当应用于口腔粘膜时,该膜不引起异物感,并且在制备过程中具有极好的便利性和效率。 构成:口腔粘膜粘附膜包括:含有5〜80重量%的聚丙烯酸类聚合物和纤维素系聚合物的粘合层,5〜70重量%的泊洛沙姆,0.05〜20重量% 通过口腔粘膜吸收的药物和0.1〜10重量%的增塑剂; 和含有5〜50重量%水不溶性水不渗透性聚合物和0.1〜10重量%增塑剂的保护层。 该膜具有50至300微米的厚度。

    카바페넴 항생물질의 중간체 및 그의 제조방법
    68.
    发明授权
    카바페넴 항생물질의 중간체 및 그의 제조방법 失效
    카바페넴항생물질의의간및및및및법법법

    公开(公告)号:KR100385364B1

    公开(公告)日:2003-05-27

    申请号:KR1020020052421

    申请日:2002-09-02

    Abstract: PURPOSE: Provided are azetidinone compound of the formula(I) as an intermediate useful for the manufacture of carbapenem antibiotics and a process for the preparation thereof. CONSTITUTION: The azetidine compound is represented by the formula(I). It is useful as an intermediate for the manufacture of beta-methylcarbapenem antibiotics and manufactured by reacting 4-acetoxy-azetidine compound of the formula(II) and alpha-halo propionic acid amide compound of the formula(III).

    Abstract translation: 目的:提供式(I)的氮杂环丁酮化合物作为可用于制备碳青霉烯类抗生素的中间体及其制备方法。 构成:氮杂环丁烷化合物由式(I)表示。 它可用作制备β-甲基碳青霉烯类抗生素的中间体,并通过使式(II)的4-乙酰氧基 - 氮杂环丁烷化合物与式(III)的α-卤代丙酰胺化合物反应制备。

Patent Agency Ranking